OrthoPediatrics Corp. $KIDS Stock: Riverbridge Partners LLC Increases Stake

Riverbridge Partners LLC lifted its position in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) by 108.9% during the third quarter, Holdings Channel reports. The institutional investor owned 324,447 shares of the company’s stock after purchasing an additional 169,132 shares during the period. Riverbridge Partners LLC’s holdings in OrthoPediatrics were worth $7,225,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in OrthoPediatrics by 70.3% in the 3rd quarter. GAMMA Investing LLC now owns 1,165 shares of the company’s stock worth $26,000 after buying an additional 481 shares during the period. Legal & General Group Plc bought a new stake in OrthoPediatrics during the second quarter valued at about $34,000. Quantinno Capital Management LP bought a new stake in OrthoPediatrics during the first quarter valued at about $160,000. Waverly Advisors LLC bought a new stake in OrthoPediatrics during the first quarter valued at about $184,000. Finally, Bank of America Corp DE purchased a new position in shares of OrthoPediatrics in the second quarter valued at about $268,000. Hedge funds and other institutional investors own 69.05% of the company’s stock.

Insiders Place Their Bets

In other OrthoPediatrics news, Director David Pelizzon sold 302,369 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the completion of the transaction, the director owned 6,201,764 shares of the company’s stock, valued at $130,299,061.64. This represents a 4.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Squadron Capital Llc sold 302,369 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the transaction, the insider owned 6,201,764 shares of the company’s stock, valued at approximately $130,299,061.64. The trade was a 4.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,100,000 shares of company stock worth $46,747,931 in the last 90 days. 32.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on KIDS shares. Canaccord Genuity Group upped their price objective on OrthoPediatrics from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, October 28th. Stifel Nicolaus increased their target price on OrthoPediatrics from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Lake Street Capital lifted their target price on OrthoPediatrics from $34.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Piper Sandler reissued an “overweight” rating and issued a $30.00 price target (up from $25.00) on shares of OrthoPediatrics in a report on Wednesday, October 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of OrthoPediatrics in a report on Tuesday, November 3rd. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $30.75.

OrthoPediatrics Price Performance

Shares of NASDAQ:KIDS opened at $33.48 on Wednesday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.00 and a current ratio of 4.55. The firm has a fifty day moving average price of $24.47 and a 200 day moving average price of $20.08. OrthoPediatrics Corp. has a fifty-two week low of $14.42 and a fifty-two week high of $34.53. The firm has a market cap of $874.16 million, a price-to-earnings ratio of -23.41 and a beta of 0.90.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Tuesday, October 27th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.02). The company had revenue of $72.66 million for the quarter, compared to analysts’ expectations of $68.50 million. OrthoPediatrics had a negative net margin of 12.83% and a negative return on equity of 8.10%. As a group, sell-side analysts expect that OrthoPediatrics Corp. will post -1.09 earnings per share for the current fiscal year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp. develops and markets orthopedic implants and instruments designed specifically for children and adolescents. Its products support surgeons treating a range of pediatric conditions, including fractures, spinal deformities, limb-length differences and other orthopedic disorders. The company’s portfolio includes systems for trauma and deformity correction, scoliosis treatment, limb lengthening and external fixation, as well as specialized surgical instruments. It also provides related education and support for pediatric orthopedic surgeons and care teams.